Nature versus Number: Monocytes in Cardiovascular Disease

Area of Science:

• Immunology
• Cardiovascular Medicine
• Atherosclerosis Research

Background:

• Monocyte influx into the vessel wall is crucial for atherosclerotic plaque development in cardiovascular disease (CVD).
• Monocytes exhibit heterogeneity, with distinct classical, intermediate, and nonclassical subsets.
• Elevated proportions of intermediate and nonclassical monocytes are observed in CVD patients, suggesting functional roles beyond mere increased numbers.

Purpose of the Study:

• To explore the nature and number of monocyte subsets in the context of cardiovascular disease (CVD).
• To investigate the emergence of altered monocyte subset proportions and functions in dyslipidemia.
• To assess the impact of lipid-lowering medication on these monocyte alterations and their implications for plaque development.

Main Methods:

• Review of existing literature on monocyte subset dynamics in cardiovascular disease (CVD).
• Analysis of emerging evidence regarding monocyte changes in dyslipidemia.
• Evaluation of the effects of lipid-lowering treatments on monocyte subsets and inflammatory markers.

Main Results:

• Increased percentages of intermediate and nonclassical monocytes are associated with cardiovascular disease (CVD).
• Changes in monocyte proportion and function are linked to dyslipidemia.
• Lipid-lowering medications show potential in reversing some of these observed monocyte alterations.

Conclusions:

• Understanding the specific roles and changes in monocyte subsets is vital for comprehending cardiovascular disease (CVD) pathogenesis.
• Dyslipidemia significantly influences monocyte subset distribution and function, offering therapeutic targets.
• Lipid-lowering therapies may modulate monocyte populations, potentially influencing atherosclerotic plaque development and clinical outcomes.